GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Net Change in Cash

Cannara Biotech (TSXV:LOVE) Net Change in Cash : C$7.62 Mil (TTM As of Nov. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Cannara Biotech's Net Change in Cash for the three months ended in Nov. 2024 was C$3.64 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Nov. 2024 was C$7.62 Mil.

Cannara Biotech Net Change in Cash Historical Data

The historical data trend for Cannara Biotech's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Net Change in Cash Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Net Change in Cash
Get a 7-Day Free Trial -18.74 0.39 3.96 -7.84 2.35

Cannara Biotech Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.63 0.49 2.33 1.16 3.64

Cannara Biotech Net Change in Cash Calculation

Cannara Biotech's Net Change in Cash for the fiscal year that ended in Aug. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=10.683+-5.188+-3.145+0
=2.35

Cannara Biotech's Net Change in Cash for the quarter that ended in Nov. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=5.834+-1.174+-1.02+0
=3.64

Net Change in Cash for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$7.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Net Change in Cash
Comparable Companies
TSX:CRDL TSXV:RX XCNQ:PLTH XCNQ:AAWH.U TSX:XLY TSXV:SBBC TSX:HLS XCNQ:JUSH TSX:MDP TSXV:HASH ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
LOVFF:USA 8CB0:Germany
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Website
http://www.cannara.ca
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Executives
Nicholas Sosiak Senior Officer
Donald John Olds Director
Olymbec Investments Inc. 10% Security Holder
Derek Elan Stern Director
Scott Carroll Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Zohar Krivorot Director, Senior Officer
Brian Sherman Senior Officer
Avi Krivorot Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Lennie Ryer Senior Officer
Jack M. Kay Director
Donal Carroll Director or Senior Officer of 10% Security Holder